| HOME >> BIOLOGY >> TECHNOLOGY |
BETHESDA, Md., Sept. 3 /PRNewswire-FirstCall/ -- Spherix Inc. (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that Dr. Claire Kruger, Chief Executive Officer, and Dr. Robert Lodder, President, will be presenting a corporate overview at the Rodman & Renshaw 11(th) Annual Healthcare Conference at 1:10 PM ET on Friday, September 11, 2009, at the New York Palace Hotel in New York City. The conference will be held from September 9-11, 2009.
A live audio and archived webcast of Spherix's presentation will be available through the Investor Relations section of the Company's website.
About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries--Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Sec
'/>"/>
| SOURCE Spherix Incorporated Copyright©2009 PR Newswire. All rights reserved |